Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Precision BioSciences Inc DTIL

Healthcare Biotechnology
Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company's pipeline consists of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform develops in vivo gene editing therapies for gene edits, including gene... see more

Recent & Breaking News (NDAQ:DTIL)

Precision BioSciences Announces Oral Presentation of Positive ARCUS® Gene Editing Data at International Liver Congress 2023

Business Wire June 22, 2023

Precision BioSciences to Present at Upcoming June Investor Conferences

Business Wire June 5, 2023

Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward

Business Wire May 31, 2023

Precision BioSciences to Provide an Update on its Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on May 31, 2023

Business Wire May 25, 2023

Precision BioSciences to Participate in Upcoming Stifel Genetic Medicines Day

Business Wire May 24, 2023

Precision BioSciences Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at the American Society of Gene & Cell Therapy 26th Annual Meeting

Business Wire May 19, 2023

Precision BioSciences Announces Publication of its Preclinical In Vivo Gene Editing Abstract on Duchenne Muscular Dystrophy Program for the American Society of Gene & Cell Therapy 26th Annual Meeting

Business Wire May 12, 2023

Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update

Business Wire May 9, 2023

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Business Wire May 8, 2023

Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023

Business Wire May 2, 2023

Precision BioSciences to Present Preclinical In Vivo Gene Editing Research for its ARCUS HBV Program at Upcoming Global Hepatitis Summit 2023

Business Wire April 20, 2023

Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting

Business Wire April 18, 2023

Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease

Business Wire April 13, 2023

Precision BioSciences to Participate in Upcoming Guggenheim Healthcare Talks Conference

Business Wire March 27, 2023

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

Business Wire March 9, 2023

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2022 Results on March 9, 2023

Business Wire March 2, 2023

Precision BioSciences Announces Senior Leadership Promotions and Organizational Changes

Business Wire February 24, 2023

Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual Conference

Business Wire February 22, 2023

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Business Wire February 14, 2023

Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones

Business Wire January 9, 2023